BIOCON, Author at Biocon

Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Biocon Q4 FY17 Revenue Rs 974 Cr; Net Profit Rs 127 Cr; FY17 Revenue at Rs 4,079 Cr; Net Profit at Rs 612 Cr

U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon’s Proposed Biosimilar Pegfilgrastim for Review

Biocon Foundation & Department of Medical, Health & Family Welfare, Govt. of Karnataka Collaborate to Set Up Smart eLAJ Clinics in Karnataka

Biocon Wins MYR 300 Million Contract for Insulin from MoH, Malaysia

Biocon Q3 FY17 Net Profit Up 65% at Rs 171 Crore Revenue Rises 32% at Rs 1092 Crore; EBITDA Increases 57% to Rs 324 Crore

U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon’s Proposed Biosimilar Trastuzumab

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon’s Proposed Biosimilar Trastuzumab Phase 3 Data

Biocon Features in Asia IP Elite 2016 List

Biocon’s Novel Diabetes Education Initiative for Medical Practitioners ‘ABIDE’ Awarded by RSSDI

Biocon Collaborates with Healthcare Professionals for a Public Awareness Campaign on Diabetes Prevention & Management Across India